The following is a summary of the KP Tissue Inc. (KPTSF) Q3 2024 Earnings Call Transcript:

Financial Performance:

• KP Tissue Inc. reported a significant revenue growth of 10.1% in Q3 2024, driven by higher sales volumes and favorable pricing, along with a positive foreign exchange impact.

• Adjusted EBITDA was $65.7 million, reflecting a decrease of 9.3% year-over-year, primarily due to higher pulp prices and increased outsourcing activity.

• Net income saw an increase of $5.1 million year-over-year, totalizing $18 million for the quarter, benefited from higher FX gains and lower income tax expense.

Business Progress:

• The newly built manufacturing plant in Sherbrooke started operations ahead of schedule with its LDC paper machine, adding 60,000 metric tons to its capacity, aiming to produce over 130,000 metric tons at maturity.

• Launched new marketing campaigns for Sponge Towels and Scotties, and maintained a focus on environmentally conscious consumers with the Bonterra brand.

• Achieved leadership position with a 44.1% share in the Canadian facial tissue market.

Opportunities:

• Continued US sales growth and recent price increases across North America present significant revenue opportunities, alongside the integration and ramp-up of new facilities, such as the Sherbrooke plant, that should economize costs and increase capacity.

• Investment in environmentally sustainable products like Bonterra branding targets environmentally conscious consumers, expanding market share.

Risks:

• Adjusted EBITDA was negatively impacted by higher pulp costs and additional outsourcing activity, with rising freight rates also affecting profitability. Dependency on outsourcing and high operational costs pose risks if not mitigated.

• Market pulp prices are expected to remain volatile in 2025, along with a weakening Canadian dollar impacting costs.

Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.